BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31290759)

  • 1. Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.
    Chami R; Marrano P; Teerapakpinyo C; Arnoldo A; Shago M; Shuangshoti S; Thorner PS
    Am J Surg Pathol; 2019 Sep; 43(9):1203-1211. PubMed ID: 31290759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
    Cheung NK; Zhang J; Lu C; Parker M; Bahrami A; Tickoo SK; Heguy A; Pappo AS; Federico S; Dalton J; Cheung IY; Ding L; Fulton R; Wang J; Chen X; Becksfort J; Wu J; Billups CA; Ellison D; Mardis ER; Wilson RK; Downing JR; Dyer MA;
    JAMA; 2012 Mar; 307(10):1062-71. PubMed ID: 22416102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
    Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
    Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.
    van Gerven MR; Bozsaky E; Matser YAH; Vosseberg J; Taschner-Mandl S; Koster J; Tytgat GAM; Molenaar JJ; van den Boogaard M
    Cancer Sci; 2022 Jun; 113(6):2167-2178. PubMed ID: 35384159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 11. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential nuclear ATRX expression in sarcomas.
    Koelsche C; Renner M; Johann P; Leiss I; Sahm F; Schimmack S; Wardelmann E; Renker EK; Schirmacher P; Korshunov A; von Deimling A; Mechtersheimer G
    Histopathology; 2016 Apr; 68(5):738-45. PubMed ID: 26291601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
    Hartlieb SA; Sieverling L; Nadler-Holly M; Ziehm M; Toprak UH; Herrmann C; Ishaque N; Okonechnikov K; Gartlgruber M; Park YG; Wecht EM; Savelyeva L; Henrich KO; Rosswog C; Fischer M; Hero B; Jones DTW; Pfaff E; Witt O; Pfister SM; Volckmann R; Koster J; Kiesel K; Rippe K; Taschner-Mandl S; Ambros P; Brors B; Selbach M; Feuerbach L; Westermann F
    Nat Commun; 2021 Feb; 12(1):1269. PubMed ID: 33627664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.
    Zhang J; Jiang J; Luo Y; Li X; Lu Z; Liu Y; Huang J; Hou Y; Pang Y; Sun MYF; Wang TS; Evans DB; Pacak K; Zhuang Z; Gao X
    Endocrine; 2018 Aug; 61(2):216-223. PubMed ID: 29846902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
    Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA
    Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult-onset neuroblastoma: Report of seven cases with molecular genetic characterization.
    Duan K; Dickson BC; Marrano P; Thorner PS; Chung CT
    Genes Chromosomes Cancer; 2020 Apr; 59(4):240-248. PubMed ID: 31749253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
    Brügger F; Dettmer MS; Neuenschwander M; Perren A; Marinoni I; Hewer E
    J Neuropathol Exp Neurol; 2017 Jan; 76(1):61-66. PubMed ID: 28040793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
    Nguyen DN; Heaphy CM; de Wilde RF; Orr BA; Odia Y; Eberhart CG; Meeker AK; Rodriguez FJ
    Brain Pathol; 2013 May; 23(3):237-43. PubMed ID: 22928601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
    Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
    Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.